Online - 2455-3891
Print - 0974-2441
Vol 11, Issue 12, 2018
Research Article
MORINDA COREIA HAS AN ANTI-HELICOBACTER PYLORI EFFECT AGAINST THE
MULTIDRUG-RESISTANT CLINICAL ISOLATE OF NORTH-EAST INDIA
SHWETA MAHANT1, VALENTINA GEHLOT1, SHANU HODA1, POOJA VIJAYARAGHAVAN1, SELVAMURTHY W1,
THIRUMURTHY N3, RAJASHREE DAS1*
1
Amity Institute of Biotechnology, Amity University, Noida, Uttar Pradesh, India. 2Amity Science, Technology & Innovation Foundation,
Amity University, Noida, Uttar Pradesh, India. 3BT Herbal, Sivakasi, Tamil Nadu, India. Email: rajashreepatra79@yahoo.co.in
Received: 23 June 2018, Revised and Accepted: 21 August 2018
ABSTRACT
Objective: Antimicrobial resistance is a growing problem in Helicobacter pylori eradication which is a microaerophilic bacterium causing various
gastroduodenal diseases. The present study has been designed to test the efficacy of Morinda coreia against the metronidazole clarithromycin and
levofloxacin-resistant H. pylori strains isolated from the biopsy taken from the patient suffering from gastric erosion in Guwahati, Assam.
Method: The antimicrobial activity of n-hexane and chloroform extract of M. coreia was tested against multidrug-resistant H. pylori isolate of Guwahati,
Assam, by agar well method and microdilution method.
Result: In the present study, the H. pylori strain resistant for metronidazole (minimal inhibitory concentration [MIC] >64 µg/mL), clarithromycin at
(MIC >0.5 µg/mL), and levofloxacin at (MIC >1 µg/mL) was tested against the n-hexane and chloroform extract of M. coreia. Both the extracts of M.
coreia showed good efficacy against the multidrug-resistant strain of H. pylori shown inhibition at 1.2 µg/mL with n-hexane extract and 2 µg/mL with
chloroform extract of M. coreia.
Conclusion: The prevalence of metronidazole-resistant ranges between 50% and 90% in the developing countries, including India, clarithromycin
ranges from 0% to 15% in India, and levofloxacin ranges between 50% and 70% in India, so there is a need of alternative therapy for the eradication
of this bacterium from the stomach. Hence, this study suggests that M. coreia, which has been used traditionally as a folk medicine for the treatment
of many gastric diseases, has also shown good efficacy against the multidrug-resistant H. pylori strain of North-east India.
Keywords: Helicobacter pylori, Morinda coreia, Resistance, Antibiogram.
© 2018 The Authors. Published by Innovare Academic Sciences Pvt Ltd. This is an open access article under the CC BY license (http://creativecommons.
org/licenses/by/4. 0/) DOI: http://dx.doi.org/10.22159/ajpcr.2018.v11i12.28064
INTRODUCTION
The Gram-negative, microaerophilic gastric bacteria Helicobacter
pylori is recognized as an important human pathogen and classified
as a Group I carcinogen by the International Agency for Research on
Cancer [1]. H. pylori has infected over half of the world’s population,
and its infection usually occurs in early childhood and can persist
throughout a lifespan if it is untreated with a specific antibiotic regimen
[2]. H. pylori infections are largely asymptomatic, but the studies have
also shown that, if its association lasts for long term with the host, it
can cause more serious disease such as gastritis, peptic ulcer, gastric
cancer, gastric adenocarcinoma, and mucosa-associated lymphoid tissue
lymphoma [3,4]. H. pylori eradication from the infected individuals is the
best and only choice for an effective treatment of its associated diseases.
Eradication by triple therapy regimen consists of a proton-pump
inhibitor in combination with two antibiotics, such as clarithromycin
and amoxicillin or metronidazole, which has been recommended as the
first-line therapy and results in a high eradication rate [5]. The other
antibiotics which are also used for the eradication of H. pylori as a
second-line therapy or third-line therapy are levofloxacin, furazolidone,
and tetracycline. Due to the use of these antibiotics for the treatment
of other diseases like respiratory, anaerobic infection, dental infection,
which have resulted in the emergence of antibiotic resistance which
may be the major cause of treatment failure [6,7]. Metronidazole and
clarithromycin are the most commonly used antibiotics in the treatment
of H. pylori infection as compared to other antibiotics, but many studies
from India and abroad have reported that the resistance for both the
antibiotics has been increasing nowadays which may be the reason for
the treatment failure [8-10]. The prevalence of dual drug resistance and
multidrug resistance has been observed in many countries which has
also become the major obstacle in the treatment for H. pylori infection.
In the geographical areas where the resistance rate ranges between 15%
and 90%, there is an urgent need to develop new treatment strategies
for H. pylori infection. Unlike synthetic drugs, bioactive natural products
which are benefical without any side effects as they are part of our day
to day life and other culinary items [11]. In this search, Morinda coreia
which is generally found in dry forests of the greater part of India and Sri
Lanka belongs to the family Rubiaceae, which is one of the largest and
the most widely distributed plants in approximately 400 genera in this
family. M. coreia is also known by its Tamil name as “Nuna.” The plant is
small- to medium-sized tree with a straight cylindrical stem 3.6–4.2 m
in length and 90 cm in width [12,13]. However, it has been shown that
the beverage produced by fermenting the fruits was able to inhibit
enteropathogenic bacteria and also had a high amount of potassium.
It is also extensively used in Thai traditional medicine to cure stomach
infection and blood stasis [14]. A dye obtained from the root bark is used
for coloring linen and woolen goods [14]. Studies have conducted using
extracts of M. coreia against various Gram-negative and Gram-positive
pathogenic bacteria but not with H. pylori [15]. Therefore, in the present
study, we tested the antimicrobial activity of M. coreia against the
multidrug-resistant strain of H. pylori isolated from the patient suffering
from gastric erosion in North-East India.
METHODS
Source of plant material
Healthy leaves of M. coreia were collected from Sivakasi, Tamil Nadu,
India. The leaves of M. coreia were authenticated at the Botany
Mahant et al.
Asian J Pharm Clin Res, Vol 11, Issue 12, 2018, 143-148
Department of Amity University. The leaves were washed properly
under running tap water and then rinsed in distilled water. Then, it was
air dried in the shade and grinded into powder using mortar and pestle.
Extract preparation of M. coreia
To obtain the extract of M. corea, 100 g of leaves was crushed with
mortar and pestle and sieved. The dried powder was then extracted
with 400 mL of n-hexane, chloroform, methanol, water, and ethanol
consecutively for 72 h solvent under constant stirring. The extract was
then filtered and dried under pressure and resuspended in the solvents.
The concentrated extract was then kept in the dark bottles at 4°C until
used. The n-hexane and chloroform extracts of M. coreia were used in
the present study to test the antimicrobial activity against multidrugresistant H. pylori isolates from North-East India.
Isolation of H. pylori strains and culture
The patient suffering from gastric erosion was included in the study. The
H. pylori strains were isolated from the antral biopsies of the patient who
underwent endoscopy procedure in the Gastroenterology Department
of Gauhati Medical College, Guwahati, Assam. The identification of the
H. pylori was done on the basis of colony morphology, gram staining,
and positive reaction in the biochemical test (catalase, urease, and
oxidase). H. pylori strain was isolated and cultured on brain heart
infusion (BHI) agar (Difco Laboratories, Detroit, MI) supplemented with
5% horse serum (Invitrogen, NY), 0.4% IsovitaleX (Becton Dickinson,
MD), trimethoprim (5 μg/mL), vancomycin (8 μg/mL), and polymixin B
(10 μg/mL). The plates were incubated at 37°C under microaerophilic
condition (5% O2, 10% CO2, and 85% N2) (Double gas incubator, Hera
cell 150i) for 3–6 days. Stock cultures were maintained until use at
–80°C in BHI broth with 20% glycerol.
Suspension preparation of H. pylori strain
The bacterial suspension of H. pylori was prepared by direct colony
method [16]. The colonies were taken directly from the plate and were
suspended in 5 mL of sterile 0.85% phosphate buffer saline (PBS). The
turbidity of the initial suspension was adjusted by comparing with
McFarland’s standard number 2 (which contains about 1×108 colonyforming units (CFU)/mL) [17].
Antimicrobial susceptibility and resistance determination
Exponentially grown H. pylori cells on antibiotic-free BHI agar were
further suspended in PBS buffer, 10-fold serial dilution of these cell
suspensions was prepared, and 10 μL of each dilution was spotted
on freshly prepared BHI agar containing various concentrations of
different antibiotics in μg/mL, namely metronidazole (0.2, 0.5, 1.5, 3, 8,
16, 32, and 64), clarithromycin (0.125, 025, 1, and 2), furazolidone (0.2,
0.5, 1, and 2), amoxicillin (0.125, 0.25, 1, and 2), levofloxacin (0.2, 0.4, 1,
and 2), and tetracycline (1, 2, 3, and 4).
Determination of minimum inhibitory concentration (MIC) by
agar dilution method
The antibiotics plates with H. pylori cultures were incubated for 72 h
under microaerophilic conditions; the MIC was defined as the lowest
concentration that inhibited visible growth of organisms. The H. pylori
isolates are considered to be resistance if the MIC for different antibiotics
is metronidazole (>8 μg/mL) [18], clarithromycin (>0.5 μg/mL) [18],
amoxicillin (>0.12 μg/mL) [18], tetracycline (>1 μg/mL) [18],
levofloxacin (>1 μg/mL) [18], and furazolidone (>2 μg/mL) [17].
Conformation of antibiotic resistance by sequence analysis of 23S
rRNA, gyraseA, rdx, and frx genes of H. pylori isolate
Antibiotic-resistant strain by agar dilution method was further
confirmed by polymerase chain reaction (PCR) followed by sequencing
for the amplification of 23S rRNA, gyraseA, rdx, and frx gene mutations
responsible for the resistance of clarithromycin, levofloxacin, and
metronidazole, respectively. Genomic DNA was isolated from the H.
pylori strain by C-TAB method [19], and the total DNA concentration was
determined by NanoDrop 1510 (IS10-03571C, Multiskan GO, Thermo
Fisher Scientific). The PCR for 23S rRNA, gyraseA, rdx, and frx gene was
performed to detect the resistance for all the antibiotics. All the genes
were amplified using the primer sets as listed in Table 1. The PCR was
carried out in 20 µL reaction containing 10 pmol dNTP (Bangalore
Genei, Bengaluru, India), 10 pmole primer sets (Sigma-Aldrich), 1.5U
Taq DNA polymerase (Bangalore Genei), and 10 ng of H. pylori-positive
genomic DNA Eppendorf Thermocycler (vapo.protectTM) for 35 cycles
under the following cycling conditions 94°C for 1 min, annealing
for 1 min, and 72° for 1min. The product was finally analyzed in 2%
agarose gel stained with ethidium bromide under standard procedure.
All the amplified PCR products were further purified by QIAquick PCR
Purification kit (QIAGEN, Hilden, Germany). The purified products were
further sequenced by ABI sequencer 3100XL consisting of Big DyeR
Terminator (PerkinElmer) with Ampli Taq FS. The sequence was edited
after aligning with SeqMan program (DNASTAR Inc., Madison, WI). For
the detection of point mutation in various genes of H. pylori, multiple
sequence alignment was performed by CLUSTAL OMEGA taking 26695
strains of H. pylori as a reference strain.
Anti-H. pylori activity of M. coreia against multidrug-resistant
strain
MIC determination by the agar well method
The different concentration of n-hexane and chloroform extract of
M. coreia was loaded into the well of 6 mm in diameter in inoculated
plates with 3 × 109 CFU of multidrug-resistant strain of H. pylori isolated
from the patient of North-East India. The plates were kept under
microaerophilic conditions (5% O2, 10% CO2, and 85% N2) for 2 days at
37°C. All experiments were performed in triplicates. Pure n-hexane and
chloroform were used as a negative control, and amoxicillin was used
as positive control.
MIC determination by microdilution method
The 96-well microtiter plate was prepared by dispensing 80 μL of
BHI broth into first well. A 20 μL from the stock solution of M. coreia
extract (120 μg/mL) was added to the first well. Then, five-fold serial
dilution was performed until 8th well. The obtained concentration
range was from 12 μg/mL to 12 × 10−7 μg/mL. To each well, 150 μL
of the diluted bacterial cells was added to give a final concentration
of 3 × 109 CFU/mL. The inoculated plates were incubated at 37°C for
72 h under microaerophilic conditions. MIC90 was defined as the lowest
concentration of extract sample that inhibited the 90% of H. pylori cells
when compared to control, i.e., H. pylori cells without extract sample.
Reading was noted on the Elisa reader (Erba Lisa Scan II).
Table 1: PCR primers of 23S rRNA, gyraseA, rdx, and frx genes of H. pylori
Gene
Primer sequence
Size of the product
References
23S rRNA
F-5ˈGGCTCTTTGAGTCCTTTAGGACAA-3ˈ forward sense positions 2020-2044 of U27270)
R-3ˈCTCCATAAGAGCCAAAGCCCTTACT-5ˈ reverse antisense position 2612-2636 of U27270)
F-5ˈ-TTTRGCTTATTCMATGAGCGT-3ˈ
R-3ˈ -GCAGACGGCTTGGTARAATA-5ˈ
F-5ˈ-GCAGGAGCATCAGATAGTTCT-3ˈ
F-3ˈ-GGGATTTTATTGTATGCTACAA-5ˈ
F-5ˈ-GGATATGGCAGCCGTTTATCATT -3ˈ
F-3ˈ-GAATAGGCATCATTTTAAGAGATT -5ˈ
613
[20]
428
[21]
886
[22]
780
[22]
gyraseA
rdx
frx
F: Forward primer; R: Reverse primer; bp: Base pairs, PCR: Polymerase chain reaction
144
Mahant et al.
Asian J Pharm Clin Res, Vol 11, Issue 12, 2018, 143-148
Rapid urease test (RUT)
For the microbial growth visualization, RUT was done. The basis
of the test is the ability of H. pylori to secrete urease enzyme which
hydrolyzes the urea to ammonia and carbon dioxide and raises the
pH of the medium from yellow (H. pylori negative) to a pink color (H.
pylori positive). MIC was defined as the lowest concentration of extract
sample that prevented RUT medium color change from yellow to pink.
RESULT
One clinical isolate was included in the study from the patient
suffering from gastric erosion. The MIC for various antibiotics, namely
metronidazole, clarithromycin, amoxicillin, tetracycline, levofloxacin,
and furazolidone, was determined by agar dilution method against H.
pylori isolate of North-East India. The strain which was selected to test
the efficacy of M. corea was multidrug resistant showing resistance
against metronidazole at the MIC of >64 µg/mL, clarithromycin at MIC
>0.5 µg/mL, and levofloxacin at MIC >1 µg/mL but sensitive to other
drugs, namely furazolidone, amoxicillin, and tetracycline. The genomic
DNA was further PCR amplified for 23S rRNA, gyraseA, rdx, and frx gene
of H. pylori for sequencing and sequence analysis (Fig. 1a-c).
Sequence analysis of various genes of H. pylori for the conformation
of resistance pattern
Mutation analysis of 23S rRNA gene of H. pylori for clarithromycin
resistance
The sequence of 23S rRNA gene was aligned with the reference sequence
U27270 using CLUSTAL OMEGA for the presence of mutation at A to G
at 2142, A to G at 2143, and T to C at 2182 positions in the V domain of
23S rRNA gene of H. pylori (Fig. 2). The strong association was observed
in the agar dilution method, and sequence analysis method showed that
the H. pylori strain resistant for clarithromycin was having a mutation at
T to C at the 2182 position and MIC of >0.5 μg/mL.
Mutation analysis of gyraseA gene of H. pylori for Levofloxacin
resistance:
The resistance for levofloxacin was observed due to a mutation in
gyraseA gene of H. pylori at various amino acid positions, namely
asparagine (N) to lysine (K) at 87 position, alanine (A) to valine
(V) at 88 position, and aspartic acid (D) to glycine (G)/tyrosine (Y)/
asparagine (N) at 91 position. The H. pylori nucleotide sequence was
converted to protein sequence by EXPASY TRANSLATE TOOL and was
aligned with the reference sequence HP0701 using CLUSTAL OMEGA
for mutation analysis. Point mutation was observed from aspartic acid
(D) to glycine(G) at 91 position in gyraseA gene of H. pylori (Fig. 3). The
strong association was observed in the sequence analysis method and
agar dilution method showing MIC at >1 ug/mL for levofloxacin.
Mutation analysis of rdx and frx gene of H. pylori for metronidazole
resistance
The resistance for metronidazole was observed by the mutation in rdx
and frx gene of H. pylori at various amino acid positions as these gene
are highly conserved genes of H. pylori [22]. The H. pylori nucleotide
sequence was converted to protein sequence by EXPASY TRANSLATE
TOOL and was aligned with the reference sequence HP0954 for rdx and
HP0642 for frx using Clustal Omega. Point mutation was observed as
various amino acid positions of rdx and frx gene of H. Pylori (Fig. 4a and
b). Hence, the strong association was observed in the sequence analysis
method and agar dilution method which has shown MIC at >64 ug/mL
for metronidazole.
Agar well method to test the efficacy of M. coreia
Different concentration of n-hexane and chloroform extract of M. coreia
was loaded onto the well and was air dried. 100 μL of the suspended H.
pylori strain in PBS having McFarland 2 (1×108 CFU/mL) was spreaded
and plated onto BHI medium. The well was made in the plate using well
puncher and the wells were loaded with different concentrations of
the extract. After 72 h of incubation, we found that the n-hexane and
chloroform extract of M. coreia has anti-H. pylori activity showing the
zone of inhibition of 7 mm at 0.4 mg/mL for n-hexane extract (Fig. 5a
and b) and 7 mm for 2.4 mg/mL chloroform extract (Fig. 6a and b) by
agar well method, and the MIC of M. coreia was <12 μg/mL for n-hexane
extract and <2 μg/mL for chloroform extract against multidrugresistance H. pylori strain of North-East India by microdilution method
(Fig. 7 and Table 2).
DISCUSSION
Fig. 1: DNA amplification of Helicobacter pylori gene: (a) 23S rRNA
gene of 613bp. Lane 1 - positive control, 26695 Lane 2 H. pylori
clinical isolate,and Lane M - Marker (100bp). (b) gyraseA gene
of 428 bp. Lane 1 - positive control, 26695 Lane 2 - H. pylori
clinical isolate, and Lane M - Marker (100bp). (c) rdx and frx
gene of 886bp and 780bp. Lane1 - positive control of rdx gene,
26695 Lane 2 - H. pylori clinical isolate, Lane M - Marker (100bp),
Lane 3 - positive control of frx gene, 26695 and Lane 4 - H. pylori
clinical isolate
H. pylori have acquired antibiotic resistance for several antibiotics in
the past two decades, which is the major cause of treatment failure. The
antibiotic resistance varies geographically due to its varied use in other
diseases for the treatment of the local population. The geographical
resistance scenario of antibiotic resistance pattern provides a guideline
to all the clinicians for the treatment regimen. Previous studies have
shown that resistance toward metronidazole varies geographically
in India such as Chandigarh (38.2%) [23], Delhi NCR (48.5%) [24],
Lucknow (68%) [23], Hyderabad (100%) [23], Chennai (82.2%), [23],
Kolkata (85%) [8], Gangetic belt of North India (100%) [25], and
Gujarat (83.2%) [26]. High prevalence of metronidazole was also found
in other developing countries such as Pakistan (97.8%) [27], China
(78.8%), Nepal (88.1%), Bangladesh (77.8%), Bhutan (83%), Vietnam
(72%), and Mexico (76.3%) [28,29]. The resistance to metronidazole is
Fig. 2: Multiple sequence alignment of domain V of 23S rRNA gene of clarithromycin of Helicobacter pylori strains. The strain number is
indicated on the left-hand side of each sequence. U27270 is a representative sequence showing T to C point mutations marked in yellow at
positions 2182 of the 23S rRNA gene. Numbering of nucleotide position followed the proposed system by Taylor et al. (position [2515 373]
+ 1 = position 2143)
145
Mahant et al.
Asian J Pharm Clin Res, Vol 11, Issue 12, 2018, 143-148
Fig. 3: Multiple sequence alignment of gyraseA gene of Helicobacter pylori for levofloxacin resistance pattern. The strain number is
indicated on the left-hand side of each sequence. HP0701 is a representative sequence showing D to G point mutations marked in yellow
at amino acid positions 91 of the gyraseA gene
Fig. 4: (a) Multiple sequence alignment of rdx gene of Helicobacter pylori for metronidazole resistance pattern. The strain number is
indicated on the left-hand side of each sequence. HP0954 is a representative sequence showing multiple point mutations marked in
yellow at amino acid positions, (b) multiple sequence alignment of rdx gene of H. pylori for metronidazole resistance pattern. The strain
number is indicated on the left-hand side of each sequence. HP0642 is a representative sequence showing multiple point mutations
marked in yellow at amino acid positions
resistance for levofloxacin is due to the mutation in the amino acid
chain of gyraseA gene of H. pylori at various positions [21]. The
resistance to clarithromycin also observed and it is considered as one
of the main drugs in the treatment regime in combination with protonpump inhibitor and amoxicillin or metronidazole. The resistance to
clarithromycin also varies geographically such as Kolkata (0%) [8],
Gujarat (58.8%) [26], Delhi NCR (11.8%) [31], Lucknow (4%) [23],
Pakistan (5.4%) [27], China (12.8–23.8%), Spain (35.6), and USA
(10–15%) [32]. Hence, the emergence of resistance to various key
antibiotics, which are mainly used as a first-line or a second-line
therapy in the eradication of H. pylori, has prompted us to look into the
non-antibiotic compound that inhibits H. pylori growth.
a
b
Fig. 5: (a and b) Agar well method: Antimicrobial activity of
n-hexane extract of Morinda coreia against the multidrugresistant strains of Helicobacter pylori
due to the mutation in oxygen-insensitive NADPH nitroreductase (rdx)
and NADPH flavin oxidoreductase (frx) gene of H. pylori [22].
The resistance for levofloxacin was also reported high in many
countries such as Delhi NCR (73.2%) [30], Gujarat (13.8%) [26],
Bangladesh (66%), Bhutan (3%), and Vietnam (25%) [28,29]. The
There are many plant and plant products which are having anti-H. pylori
effect and showed good efficacy against the drug-resistant H. pylori
strain. De et al. showed the good efficacy of curcumin in H. pyloriinfected mouse [33]. Our other studies have shown that the methanolic
extract of Paederia foetida [34], methanolic and ethanolic extract
Parmelia perlata [35], Embilica officinalis [36], and methanolic and
n-hexane extract of Brassica capitata is effective against dual and
multidrug resistance H. pylori stain [37]. Our various studies prompted
us to explore the efficacy of M. coreia, which is being extensively
cultivated in India for the dye which is obtained from the root bark
and it is a popular medicinal plant in Thailand. It has been used to
146
Mahant et al.
2 μg/mL
7
Zone of inhibition (in mm)
b
Fig. 6: (a and b) Agar well method: Antimicrobial activity of
chloroform extract of Morinda coreia against the multidrugresistant strains of Helicobacter pylori
Fig. 7: Microdilution method: Lanes 1–8 show the 5-fold serial
dilution of Morinda coreia extract from Lanes 1–8 with a constant
cell count of Helicobacter pylori. Lane 9 shows the cell control
without the extract. Lane 10 shows media control without cells.
Lane 11 shows extract control without cells. Lane 12 shows the
H. pylori cell control. Minimal inhibitory concentration 90 was
observed at Lane 2 and Lane 1 for n-hexane and chloroform
extract of M. coreia, respectively
7
treat menstrual disorders, as a tonic for stomach infection and blood
stasis, and has shown antibacterial properties against Gram-negative
and Gram-positive bacteria [15,38]. In our study, we found that the
n-hexane and chloroform extract of M. coreia has shown good efficacy
against the multidrug-resistant H. pylori stain of North-East India by
agar well method and microdilution method.
H. pylori: Helicobacter pylori, M. coreia: Morinda coreia, MIC: Minimal inhibitory concentration
Zone of inhibition (in mm)
0.4
MTZ=64 µg/mL
CLR=0.5 µg/mL
LEV=1 µg/mL
Amount (in mg)
1.2 μg/mL
2.4
Amount (in mg)
a
Strain 1
Chloroform extract of M. coreia
(Agar well method)
MIC90 for M. coreia
(Microdilution method)
n-Hexane extract of M. coreia
(Agar well method)
MIC for MTZ, CLR, LEV
(agar dilution method)
Strain No.
Table 2: Antimicrobial activity of n-hexane and chloroform extract of M. coreia against multidrug-resistant H. pylori strain
MIC90 for M. coreia
(Microdilution method)
Asian J Pharm Clin Res, Vol 11, Issue 12, 2018, 143-148
However, further research needs to be done to determine the
compounds that are responsible for antibacterial activity against
multidrug-resistant H. pylori strain of North-East India.
CONCLUSION
In our present study, we have primarily shown that M. coreia, which
is a traditional plant used for the treatment of various diseases, have
potentially inhibited the growth of multidrug-resistant H. pylori in vitro
that were isolated from the patient suffering from gastric erosion. It is
noteworthy that the strain was resistant for metronidazole at MIC >
64 µg/mL, clarithromycin at MIC >0.5 µg/mL, and levofloxacin >1 µg/mL.
Overall, this study provides novel insights in the therapeutic potential of
n- hexane and chloroform extract of M. coreia against multidrug-resistant
H. pylori strain, although further studies are required to determine the
pathway of its mechanism and its active compounds.
ACKNOWLEDGMENT
We thank Amity University for providing the infrastructure and support
to carry out the research work.
AUTHORS’ CONTRIBUTION
RD has given the concept of antibiogram profiling of H. pylori strains.
RD and PV have finalized the manuscript. SM has performed the
experiments, analyzed the data, and drafted the manuscript. WS and NT
have provided the M. coreia sample. VG and SH have performed some of
the experiments.
147
Mahant et al.
Asian J Pharm Clin Res, Vol 11, Issue 12, 2018, 143-148
CONFLICTS OF INTEREST
The authors declared they have no conflicts of interest.
FUNDING
This study was supported by the Department of Biotechnology (DBT)
grant no. (BT/240/NE/TBP/2011)
REFERENCES
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
17.
18.
19.
20.
Dunn BE, Cohen H, Blaser MJ. Helicobacter pylori. Clin Microbiol
1997;10:720-41.
Blaser MJ. Epidemiology and pathophysiology of Campylobacter
pylori infections. Infect Dis 1990;12 Suppl 1:S99-106.
Matthews GM, Butler RN. Cellular mucosal defense during
Helicobacter pylori infection: A review of the role of glutathione and
oxidative pentose pathway. Helicobacter 2005;10:298-306.
Montecucco C, Rappuoli R. Living dangerously: How Helicobacter
pylori survive in the human stomach. Nat Rev Mol Cell Biol
2001;2:457-66.
Toracchio S, Cellini L, Di Campli E, Cappello G, Malatesta MG,
Ferri A, et al. Role of antimicrobial susceptibility testing on efficacy
of triple therapy in Helicobacter pylori eradication. Aliment Pharmacol
Ther 2000;14:1639-43.
Bytzer P, O’Morain C. Treatment of Helicobacter pylori. Helicobacter
2005;10:40-6.
Cameron EA, Powell KU, Baldwin L, Jones P, Bell GD, Williams SG,
et al. Helicobacter pylori: Antibiotic resistance and eradication rates in
suffolk, UK, 1991-2001. J Med Microbiol 2004;53:535-8.
Datta S, Chattopadhyay S, Patra R, De R, Ramamurthy T, Hembram J,
et al. Most Helicobacter pylori strains of Kolkatta in India are resistant
to metronidazole but susceptible to other drugs commonly used for
eradication and ulcer therapy. Aliment Pharmacol Ther 2005;22:51-7.
Das R, Gehlot V, Mahant S, Mukhopadhyay AK, Das K. High
prevalence of single, dual, and multidrug resistant Helicobacter pylori
infection in India. Helicobacter 2015;20 Suppl 1:P03.18.
Miyazi H, Azuma T, Ito S, Suto H, Ito Y, Yamazaki Y. Susceptibility
of Helicobacter pylori isolates to metronidazole, clarithromycin
and amoxicillin in vitro and in clinical treatment in Japan. Aliment
Pharmacol Ther 1997;11:1131-6.
Kiritikar KR, Basu BD. Indian Medicinal Plants. 3rd ed. Allahabad:
Lalit Mohan Basu MB; 1996. p. 2757.
Singh J, Tiwari RD. Flavone glycosides from the flowers of Morinda
species. J Ind Chem Soc 1976;53:424.
Matthew KM. The Flora of the Tamilnadu Carnatic. Tiruchirappalli:
The Rapinat Herbarium, St. Joseph’s College; 1983. p. 1-3, 718.
Kantachote D, Kowpong K, Charernjiratrakul W, Pengoo A. The
possibilities of using the fruit of Morinda coreia to make a liquid
manure. Electron J Biotechnol 2009;12:1-11.
Antonysamy K, Soosai S, Sebastin S, Prakasam R. Biosynthesis
of silver nanoparticles from Morinda Coreia Buch.-Ham. And it’s
antibacterial activity. Int J Pharm Sci Res 2014;5:5321-7.
Andrews JM. BSAC working party on susceptibility testing. BSAC
standardized disc susceptibility testing method. J Antimicrob
Chemother 2005;56:60-76.
Clinical Laboratory Standard Institute. Methods for Antimicrobial
Dilution and Disk Susceptibility Testing of Infrequently Isolated or
Fastidious Bacteria; Approved Guideline. 2nd ed. CLSI document
M45-A2. Vol. 30. No. 18. Wayne, PA, USA: CLSI; 2010.
EUCAST. Breakpoint Tables for Interpretation of MICs and Zone
Diameters. Version 3.1. EUCAST; 2013.
Murray MG, Thompson WF. Rapid isolation of high molecular weight
plant DNA. Nucleic Acid Res 1980;8:4321-5.
Garrido L, Toledo H. Novel genotypes in Helicobacter pylori involving
domain V of the 23S rRNAgene. Helicobacter 2007;12:505-9.
21. Moore RA, Beckthold B, Wong S, Kureishi A, Bryan LE. Nucleotide
sequence of the gyrA gene and characterization of ciprofloxacinresistant mutants of Helicobacter pylori. Antimicrob Agents Chemother
1995;39:107-11.
22. Jeong JY, Mukhopadhyay AK, Dailidiene D, Wang Y, Velapatino B,
Gilman RH, et al. Sequential Inactivation of rdxA (HP0954) and
frxA (HP0642) nitroreductase genes causes moderate and highlevel metronidazole resistance in Helicobacter pylori. J Bacteriol
2000;182:5082-90.
23. Thyagarajan SP, Ray P, Das BK, Ayyagari A, Khan AA, Dharmalingam S,
et al. Geographical difference in antimicrobial resistance pattern of
Helicobacter pylori clinical isolates from Indian patients: Multicentric
study. J Gastroenterol Hepatol 2003;18:1373-8.
24. Gehlot V, Mahant S, Mukhopadhyay AK, Das K, De R, Kar P, et al.
Antimicrobial susceptibility profiles of Helicobacter pylori isolated
from the patients in North India. J Glob Antimicrob Resist 2015;5:51-6.
25. Singh V, Mishra S, Maurya P, Rao G, Jain AK, Dixit VK, et al. Drug
resistance pattern and clonality in H. pylori strains. J Infect Dev Ctries
2009;3:130-6.
26. Pandya HB, Agravat HH, Patel JS, Sodagar NR. Emerging antimicrobial
resistance pattern of Helicobacter pylori in central Gujarat. Indian J
Med Microbiol 2014;32:408-13.
27. Rasheed F, Campbell BJ, Alfizah H, Varro A, Zahra R, Yamaoka Y,
et al. Analysis of clinical isolates of Helicobacter pylori in Pakistan
reveals high degrees of pathogenicity and high frequencies of antibiotic
resistance. Helicobacter 2014;19:387-99.
28. Kuo YT, Liou JM, El-Omar EM, Wu JY, Leow AHR, Goh KL, et al.
Primary antibiotic resistance in Helicobacter pylori in the asia-pacific
region: A systematic review and meta-analysis. Lancet Gastroenterol
Hepatol 2017;2:707-15.
29. Megraud F. Epidemiology and mechanism of antibiotic resistance in
Helicobacter pylori. Gastroenterology 1998;115:1278-82.
30. Gehlot V, Mahant S, Das R. Most of the Helicobacter pylori isolates
are resistant to levofloxacin in North India. Int J Pharm Pharm Sci
2016;8:454-6.
31. Gehlot V, Mahant S, Mukhopadhyay AK, Das K, Alam J, Ghosh P,
et al. Low prevalence of clarithromycin-resistant Helicobacter pylori
isolates with A2143G point mutation in the 23S rRNA gene in north
india. J Glob Antimicrob Resist 2016;6:39-43.
32. Ghotaslou R, Leylabadlo HE, Asl YM. Prevalence of antibiotic
resistance in Helicobacter pylori: A recent literature review. World J
Methodol 2015;5:164-74.
33. De R, Kundu P, Swarnakar S, Ramamurthy T, Chowdhury A, Nair GB,
et al. Antimicrobial activity of curcumin against Helicobacter pylori
isolates from India and during infections in mice. Antimicrob Agents
Chemother 2009;53:1592-7.
34. Chanda S, Gehlot V, Das R, Mahant S, Das K, Singh K, et al. Antimicrobial
activity of herbal extract against drug resistant Helicobacter pylori
isolates from India. World J Pharm Res 2014;3:1234-43.
35. Gehlot V, Mahant S, Vijayraghwan P, Das K, Hoda S, Das R. Therapeutic
potential of lichen Parmelia perlata against dual drug-resistant
Helicobacter pylori isolates. Int J Pharm Pharm Sci 2015;8:205-8.
36. Mehrotra S, Jamwal R, Shyam R, Meena DK, Mishra K, Patra R,
et al. Anti-Helicobacter pylori and antioxidant properties of Emblica
officinalis pulp extract: A potential source for therapeutic use against
gastric ulcer. J Med Plants Res 2011;5:2577-83.
37. Mahant S, Gehlot V, Bhatnagar S, Rikhi M, Mukhopadhyay AK,
Dutta S, et al. Antibiogram profiling of Helicobacter pylori strains and
the efficacy of Brassica capitata against resistant strains isolated from
the patients suffering from gastroduodenal diseases in Gauhati, Assam.
Asian J Pharm Clin Res 2018;11:176-80. (In Press).
38. Wang MY, West BJ, Jensen CJ, Nowicki D, Su C, Palu AK, et al.
Morinda citrifolia (Noni): A literature review and recent advances in
noni research. Acta Pharmacol 2002;12:1127-41.
148